Samcheondang Pharmaceutical: "Eylea Biosimilar U.S. Patent Settlement... Secures Local Sales Rights"
“Fresenius Kabi and Regeneron Reach Settlement”
Samcheondang Pharmaceutical announced that it has settled the U.S. patent dispute over its Eylea biosimilar and secured local sales rights.
On the 25th, Samcheondang Pharmaceutical stated in a shareholder notice that its U.S. partner, Fresenius Kabi, had finalized a patent dispute settlement with the originator company Regeneron on the 12th. Due to confidentiality provisions, the specific terms of the agreement cannot be disclosed, but the company explained that through this settlement it has secured the right to sell the Eylea biosimilar “Vizenfry (SCD411)” in the U.S. market.
In the shareholder notice, Samcheondang Pharmaceutical CEO Jeon Inseok said, “We have officially secured the sales rights in the U.S., which is the most important market,” adding, “We will proceed with our global expansion as planned without any setbacks.”
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
This settlement is also linked to the recent sharp rise in the company’s share price. Since the beginning of this year, Samcheondang Pharmaceutical’s share price has risen by more than 170%, which is seen as reflecting expectations for the global rollout of its Eylea biosimilar. In the market, analysts say that the resolution of the U.S. patent dispute has partially removed key commercialization-related uncertainties. However, since the terms of the settlement are not public, the specific launch timing and profit structure are expected to be disclosed at a later date.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.